litlas
Log inCreate account

Vassiliki A. Papadimitrakopoulou

Active 1996–2023

102
Papers
24,524
Citations
81
h-index
102
i10-index

Citations

Citations per year for Vassiliki A. Papadimitrakopoulou1951: 1 citations1997: 6 citations1998: 13 citations1999: 10 citations2000: 7 citations2001: 6 citations2002: 8 citations2003: 11 citations2004: 20 citations2005: 34 citations2006: 35 citations2007: 30 citations2008: 48 citations2009: 73 citations2010: 57 citations2011: 72 citations2012: 77 citations2013: 95 citations2014: 96 citations2015: 153 citations2016: 190 citations2017: 247 citations2018: 337 citations2019: 1,163 citations2020: 1,531 citations2021: 1,620 citations2022: 1,141 citations2023: 913 citations2024: 1,205 citations2025: 625 citations2026: 19 citations1952–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,324 citing papers, 25.9% of this breakdownChina: 2,181 citing papers, 17% of this breakdownItaly: 713 citing papers, 5.6% of this breakdownUnited Kingdom: 599 citing papers, 4.7% of this breakdownJapan: 573 citing papers, 4.5% of this breakdownFrance: 509 citing papers, 4% of this breakdownSpain: 466 citing papers, 3.6% of this breakdownGermany: 461 citing papers, 3.6% of this breakdownCanada: 366 citing papers, 2.8% of this breakdownSouth Korea: 341 citing papers, 2.7% of this breakdownNetherlands: 273 citing papers, 2.1% of this breakdownAustralia: 267 citing papers, 2.1% of this breakdown
0%25.9%Other 21.4%

Institutions

Fields

  • Medicine68.2%
  • Biochemistry, Genetics and Molecular Biology23.8%
  • Immunology and Microbiology3.4%
  • Dentistry0.9%
  • Mathematics0.8%
  • Computer Science0.7%
  • Other2.2%

Topics

  • Lung Cancer Treatments and Mutations13.5%
  • Cancer Immunotherapy and Biomarkers10.5%
  • Lung Cancer Research Studies6%
  • Cancer Genomics and Diagnostics5.3%
  • Lung Cancer Diagnosis and Treatment3.7%
  • Immunotherapy and Immune Responses2.4%
  • Other58.6%

Coauthors

All papers

Open in search
  1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

    Authors: Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Hye Ryun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Chee Khoon Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou - New England Journal of Medicine 2016 cited by 3,329

  2. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

    Authors: Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Péter M. Szabó, Chang Han, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph D. Szustakowski, Patrik Vitazka, Robin Edwards, José A. Bufill, Neelesh Sharma, Sai‐Hong Ignatius Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jiménez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galán‐Cobo, Haïfa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez‐Canales, Pamela Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino–Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok‐Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach - Cancer Discovery 2018 cited by 1,604

  3. Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Authors: Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao, Vassiliki A. Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R. Parra, Jaime Rodriguez Canales, Jianjun Zhang, Uma Giri, Jayanthi Gudikote, María Angélica Cortez, Chao Yang, You-Hong Fan, Michael Peyton, Luc Girard, Kevin R. Coombes, Carlo Toniatti, Timothy P. Heffernan, Murim Choi, Garrett M. Frampton, Vincent A. Miller, John N. Weinstein, Roy S. Herbst, Kwok‐Kin Wong, Jianhua Zhang, Padmanee Sharma, Gordon B. Mills, Waun Ki Hong, John D. Minna, James P. Allison, P. Andrew Futreal, Jing Wang, Ignacio I. Wistuba, John V. Heymach - Cancer Discovery 2015 cited by 916

  4. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

    Authors: Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin, Xiuning Le, Michael E. Goldberg, Karthikeyan Murugesan, Chang‐Jiun Wu, Jianhua Zhang, Jianhua Zhang, David S Barreto, Jacqulyne Robichaux, Alexandre Reuben, Tina Cascone, Carl M. Gay, K. G. Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Don L. Gibbons, Bonnie S. Glisson, Gaurav Singal, Vincent A. Miller, Brian M. Alexander, Garrett M. Frampton, Lee A. Albacker, David S. Shames, Jianjun Zhang, Jianjun Zhang, John V. Heymach - Journal for ImmunoTherapy of Cancer 2021 cited by 292

  5. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

    Authors: Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto, Michaela Bowden, Margaret K. Callahan, Edward Cha, Helen X. Chen, Charles G. Drake, David Feltquate, Robert L. Ferris, James L. Gulley, Shilpa Gupta, Rachel Humphrey, Theresa LaVallee, Dung T. Le, Vanessa M. Hubbard-Lucey, Vassiliki A. Papadimitrakopoulou, Michael A. Postow, Eric H. Rubin, Elad Sharon, Janis M. Taube, Suzanne L. Topalian, Roberta Zappasodi, Mario Sznol, Ryan J. Sullivan - Journal for ImmunoTherapy of Cancer 2020 cited by 280

  6. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

    Authors: Natasha B. Leighl, Ray D. Page, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona‐Calero, Daniel Dix, Justin I. Odegaard, Richard B. Lanman, Vassiliki A. Papadimitrakopoulou - Clinical Cancer Research 2019 cited by 597

  7. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

    Authors: Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Ji‐Youn Han, Nobuyuki Katakami, Hye Ryun Kim, Rachel Hodge, Paramjit Kaur, Andy Brown, Dana Ghiorghiu, Vassiliki A. Papadimitrakopoulou, Tony Mok - Journal of Clinical Oncology 2018 cited by 515

  8. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

    Authors: Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi, Susan J. Hines, Leah Everhart, Louise Highleyman, Vassiliki A. Papadimitrakopoulou, Joel W. Neal, Saiama N. Waqar, Jyoti D. Patel, Jhanelle E. Gray, David R. Gandara, Karen Kelly, Roy S. Herbst - Journal of Clinical Oncology 2022 cited by 240

  9. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Authors: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 cited by 1,392

  10. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

    Authors: Juliann Chmielecki, Tony Mok, Yi‐Long Wu, Ji‐Youn Han, Myung‐Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih‐Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki A. Papadimitrakopoulou - Nature Communications 2023 cited by 173

  11. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

    Authors: Limo Chen, Lixia Diao, Yongbin Yang, Xiaohui Yi, B. Leticia Rodriguez, Yanli Li, Pamela Villalobos, Tina Cascone, Xi Liu, Lin Tan, Philip L. Lorenzi, Anfei Huang, Qiang Zhao, Di Peng, Jared J. Fradette, David H. Peng, Christin Ungewiss, Jonathon D. Roybal, Pan Tong, Junna Oba, Ferdinandos Skoulidis, Weiyi Peng, Brett W. Carter, Carl M. Gay, You-Hong Fan, Caleb A. Class, Jingfen Zhu, Jaime Rodriguez‐Canales, Masanori Kawakami, Lauren A. Byers, Scott E. Woodman, Vassiliki A. Papadimitrakopoulou, Ethan Dmitrovsky, Jing Wang, Stephen E. Ullrich, Ignacio I. Wistuba, John V. Heymach, F. Xiao‐Feng Qin, Don L. Gibbons - Cancer Discovery 2018 cited by 471

  12. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

    Authors: Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa Laskin, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Wu‐Chou Su, Thomas John, Martin Sebastian, Helen Mann, Michele Miranda, Gianluca Laus, Yuri Rukazenkov, Yi‐Long Wu - Annals of Oncology 2020 cited by 276

  13. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

    Authors: Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada‐Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R. Brahmer, Mehmet Altan, Charles Lu, Vassiliki A. Papadimitrakopoulou, Katerina Politi, Robert C. Doebele, Kwok‐Kin Wong, John V. Heymach - Nature Medicine 2018 cited by 455

  14. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

    Authors: Xiuning Le, Sonam Puri, Marcelo V. Negrão, Monique B. Nilsson, Jacqulyne Robichaux, Theresa A. Boyle, J. Kevin Hicks, Katherine L. Lovinger, Emily Roarty, Waree Rinsurongkawong, Ming Tang, Huiying Sun, Yasir Y. Elamin, Lara Lacerda, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, William N. William, Bonnie S. Glisson, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, Jhanelle E. Gray, John V. Heymach - Clinical Cancer Research 2018 cited by 386

  15. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

    Authors: Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki A. Papadimitrakopoulou, Cara Haymaker, Harriet M. Kluger, Scott Gettinger, Mario Sznol, Scott S. Tykodi, Brendan D. Curti, Mary Tagliaferri, Jonathan Zalevsky, Alison L. Hannah, Ute Hoch, Sandra Aung, Christie Fanton, Ahsan Rizwan, Ernesto Iacucci, Yijie Liao, Chantale Bernatchez, Michael E. Hurwitz, Daniel C. Cho - Cancer Discovery 2020 cited by 238

  16. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

    Authors: Nathan T. Ihle, Lauren A. Byers, Edward S. Kim, Pierre Saintigny, J. Jack Lee, George R. Blumenschein, Anne S. Tsao, Suyu Liu, Jill E. Larsen, Jing Wang, Lixia Diao, Kevin R. Coombes, Lu Chen, Shuxing Zhang, Mena Abdelmelek, Ximing Tang, Vassiliki A. Papadimitrakopoulou, John D. Minna, Scott M. Lippman, Waun Ki Hong, Roy S. Herbst, Ignacio I. Wistuba, John V. Heymach, Garth Powis - JNCI Journal of the National Cancer Institute 2012 cited by 529

  17. Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

    Authors: Yanyan Lou, Lixia Diao, Edwin R. Parra, Warren L. Denning, Limo Chen, You Hong Fan, Lauren A. Byers, Jing Wang, Vassiliki A. Papadimitrakopoulou, Carmen Behrens, Jaime Canales Rodriguez, Patrick Hwu, Ignacio I. Wistuba, John V. Heymach, Don L. Gibbons - Clinical Cancer Research 2016 cited by 446

  18. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

    Authors: Jhanelle E. Gray, Myung‐Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng‐Chih Lin, Yi‐Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam - Clinical Cancer Research 2023 cited by 60

  19. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

    Authors: Carminia Maria Della Corte, Triparna Sen, Carl M. Gay, Kavya Ramkumar, Lixia Diao, Robert J. Cardnell, B. Leticia Rodriguez, C. Allison Stewart, Vassiliki A. Papadimitrakopoulou, Laura Gibson, Jared J. Fradette, Qi Wang, You-Hong Fan, David H. Peng, Marcelo V. Negrão, Ignacio I. Wistuba, Junya Fujimoto, Luisa M. Solis Soto, Carmen Behrens, Ferdinandos Skoulidis, John V. Heymach, Jing Wang, Don L. Gibbons, Lauren A. Byers - Journal of Thoracic Oncology 2020 cited by 204

  20. The BATTLE Trial: Personalizing Therapy for Lung Cancer

    Authors: Edward S. Kim, Roy S. Herbst, Ignacio I. Wistuba, J. Jack Lee, George R. Blumenschein, Anne S. Tsao, David J. Stewart, Marshall E. Hicks, Jeremy J. Erasmus, Sanjay Gupta, Christine Alden, Suyu Liu, Ximing Tang, Fadlo R. Khuri, Hai T. Tran, Bruce E. Johnson, John V. Heymach, Li Mao, Frank V. Fossella, Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Suzanne E. Davis, Scott M. Lippman, Waun Ki Hong - Cancer Discovery 2011 cited by 893

  21. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

    Authors: Scott Gettinger, Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, Jeffrey D. Bradley, Thomas E. Stinchcombe, Natasha B. Leighl, Suresh S. Ramalingam, Susan S. Tavernier, Hui Yu, Joseph M. Unger, Katherine Minichiello, Louise Highleyman, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara, Roy S. Herbst - JAMA Oncology 2021 cited by 104

  22. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

    Authors: Jingying Nong, Yuhua Gong, Yanfang Guan, Xin Yi, Yuting Yi, Lianpeng Chang, Ling Yang, Jialin Lv, Zhirong Guo, Hongyan Jia, Yuxing Chu, Tao Liu, Ming Chen, Lauren A. Byers, Emily Roarty, Vincent K. Lam, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, John V. Heymach, Bonnie S. Glisson, Zhongxing Liao, J. Jack Lee, P. Andrew Futreal, Shucai Zhang, Xuefeng Xia, Jianjun Zhang, Jinghui Wang - Nature Communications 2018 cited by 219

  23. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

    Authors: James W. Welsh, Chad Tang, Patricia M. de Groot, Aung Naing, Kenneth R. Hess, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Taylor R. Cushman, Vivek Subbiah, Joe Y. Chang, George R. Simon, Rishab Ramapriyan, Hampartsoum B. Barsoumian, Hari Menon, María Angélica Cortez, Erminia Massarelli, Quynh Nguyen, Padmanee Sharma, James P. Allison, Adi Diab, Vivek Verma, Uma Raju, S. Shaaban, Ramona Dadu, Maria E. Cabanillas, Kelvin Wang, Clark Anderson, Daniel R. Gomez, Stephen M. Hahn, Ritsuko Komaki, David S. Hong - Cancer Immunology Research 2019 cited by 146

  24. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

    Authors: Lingzhi Hong, Marcelo V. Negrão, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac, Xiaoke Liu, Ferdinandos Skoulidis, Carl M. Gay, Tina Cascone, K. G. Mitchell, Hai T. Tran, Xiuning Le, Lauren A. Byers, Boris Sepesi, Mehmet Altan, Yasir Y. Elamin, Frank V. Fossella, Jonathan M. Kurie, Charles Lu, Frank E. Mott, Anne S. Tsao, Waree Rinsurongkawong, Jeff Lewis, Don L. Gibbons, Bonnie S. Glisson, George R. Blumenschein, Emily Roarty, P. Andrew Futreal, Ignacio I. Wistuba, Jack A. Roth, Stephen G. Swisher, Vassiliki A. Papadimitrakopoulou, John V. Heymach, J. Jack Lee, George R. Simon, Jianjun Zhang - Journal of Thoracic Oncology 2020 cited by 192